What it is
Semaglutide is a GLP-1 receptor agonist — a peptide that mimics the gut hormone GLP-1, which your body releases after eating. It's given as a weekly injection (or a daily tablet, as Rybelsus) with a gradual dose ramp. It sits at the center of the recent wave of interest in this whole class.
How it works
By activating the GLP-1 receptor, semaglutide slows how quickly the stomach empties, increases feelings of fullness, and improves the body's blood-sugar regulation. The appetite and satiety effects are why it produces weight loss; the glucose effects are why it started as a diabetes drug. See the GLP-1 side-effects article for how this mechanism drives its side-effect profile.
The evidence
Semaglutide has a substantial clinical trial base. In head-to-head framing of the class, reviews report placebo-corrected weight loss of roughly 12% for semaglutide, compared with about 5% for older agents like liraglutide and around 18% for tirzepatide. Reviewers describe these agents as “a paradigm shift in obesity treatment.” This is the kind of large, controlled human evidence that most peptides in this directory simply do not have — a distinction worth keeping front of mind.
Side effects
Effects are predominantly gastrointestinal. In one clinical trial, roughly 44% of semaglutide patients reported nausea and about 25% reported vomiting, mostly in the first ~20 weeks and generally mild to moderate. Reviews also list less common but more serious concerns across the class, including pancreatitis, gallbladder disorders, and effects on the kidneys and thyroid signaling in animal models.
The GLP-1 side-effects article covers the common effects, the serious ones, and the stop-and-call warning signs in detail. It applies directly to semaglutide.
Regulatory status
Approved by the FDA and other regulators for type 2 diabetes and, separately, for chronic weight management, under specific brand names. It is a prescription drug, and the versions studied in trials were pharmaceutical-grade under medical supervision — a meaningful difference from research-chemical sourcing.
FAQ
Both are semaglutide, but they're branded and dosed for different approved uses — Ozempic for type 2 diabetes, Wegovy for weight management. Same molecule, different labels.
Because it chemically is one — a GLP-1 analogue. It's just an unusually well-studied, approved example, which is exactly why it's useful for comparison.
Trials and clinical experience suggest weight regain is common after stopping, which is part of why it's framed as an ongoing treatment. Discuss this with a clinician.
Sources
This profile summarizes the following. Follow the links to read the originals — and remember that summaries age, so check for newer information.
- Comparative safety and side effects of semaglutide and tirzepatide (ScienceDirect)
- GLP-1 agonists for obesity: outcomes, tolerability, side effects, risks (PMC)
- GI adverse events with GLP-1 RA: systematic review & network meta-analysis (Int. J. Obesity)
Inclusion here is not endorsement of any source's claims; several are cited so you can compare how different outlets characterize the same evidence.
Reviewed by Remy — part of the PepConnection crew.